JP5057610B2 - 自然分散性ｎ−ベンゾイルスタウロスポリン組成物 - Google Patents

自然分散性ｎ−ベンゾイルスタウロスポリン組成物 Download PDF

Info

Publication number
JP5057610B2
JP5057610B2 JP2000599363A JP2000599363A JP5057610B2 JP 5057610 B2 JP5057610 B2 JP 5057610B2 JP 2000599363 A JP2000599363 A JP 2000599363A JP 2000599363 A JP2000599363 A JP 2000599363A JP 5057610 B2 JP5057610 B2 JP 5057610B2
Authority
JP
Japan
Prior art keywords
benzoylstaurosporine
composition
surfactant
weight
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000599363A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002537242A5 (cg-RX-API-DMAC7.html
JP2002537242A (ja
Inventor
グラハム・ポール・マシューズ
バルバラ・ヘーベルリン
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10847896&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5057610(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2002537242A publication Critical patent/JP2002537242A/ja
Publication of JP2002537242A5 publication Critical patent/JP2002537242A5/ja
Application granted granted Critical
Publication of JP5057610B2 publication Critical patent/JP5057610B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2000599363A 1999-02-16 2000-02-14 自然分散性ｎ−ベンゾイルスタウロスポリン組成物 Expired - Fee Related JP5057610B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9903547.9 1999-02-16
GBGB9903547.9A GB9903547D0 (en) 1999-02-16 1999-02-16 Organic compounds
PCT/EP2000/001196 WO2000048571A1 (en) 1999-02-16 2000-02-14 Spontaneously dispersible n-benzoyl staurosporine compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012000816A Division JP2012111763A (ja) 1999-02-16 2012-01-05 自然分散性ｎ−ベンゾイルスタウロスポリン組成物

Publications (3)

Publication Number Publication Date
JP2002537242A JP2002537242A (ja) 2002-11-05
JP2002537242A5 JP2002537242A5 (cg-RX-API-DMAC7.html) 2011-02-17
JP5057610B2 true JP5057610B2 (ja) 2012-10-24

Family

ID=10847896

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000599363A Expired - Fee Related JP5057610B2 (ja) 1999-02-16 2000-02-14 自然分散性ｎ−ベンゾイルスタウロスポリン組成物
JP2012000816A Pending JP2012111763A (ja) 1999-02-16 2012-01-05 自然分散性ｎ−ベンゾイルスタウロスポリン組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012000816A Pending JP2012111763A (ja) 1999-02-16 2012-01-05 自然分散性ｎ−ベンゾイルスタウロスポリン組成物

Country Status (34)

Country Link
US (3) US20020061873A1 (cg-RX-API-DMAC7.html)
EP (1) EP1152750B1 (cg-RX-API-DMAC7.html)
JP (2) JP5057610B2 (cg-RX-API-DMAC7.html)
KR (2) KR100880859B1 (cg-RX-API-DMAC7.html)
CN (1) CN100367930C (cg-RX-API-DMAC7.html)
AR (2) AR022589A1 (cg-RX-API-DMAC7.html)
AT (1) ATE430554T1 (cg-RX-API-DMAC7.html)
AU (1) AU765776B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0008228B8 (cg-RX-API-DMAC7.html)
CA (1) CA2362277C (cg-RX-API-DMAC7.html)
CL (1) CL2009001682A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ303979B6 (cg-RX-API-DMAC7.html)
DE (1) DE60042151D1 (cg-RX-API-DMAC7.html)
DK (1) DK1152750T3 (cg-RX-API-DMAC7.html)
EC (1) ECSP083351A (cg-RX-API-DMAC7.html)
ES (1) ES2326783T3 (cg-RX-API-DMAC7.html)
GB (1) GB9903547D0 (cg-RX-API-DMAC7.html)
HK (1) HK1045807B (cg-RX-API-DMAC7.html)
HU (1) HUP0105364A3 (cg-RX-API-DMAC7.html)
ID (1) ID30504A (cg-RX-API-DMAC7.html)
IL (3) IL144512A0 (cg-RX-API-DMAC7.html)
MY (1) MY128362A (cg-RX-API-DMAC7.html)
NO (1) NO331232B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ513529A (cg-RX-API-DMAC7.html)
PE (1) PE20001499A1 (cg-RX-API-DMAC7.html)
PL (1) PL198330B1 (cg-RX-API-DMAC7.html)
PT (1) PT1152750E (cg-RX-API-DMAC7.html)
RU (1) RU2266121C2 (cg-RX-API-DMAC7.html)
SI (1) SI1152750T1 (cg-RX-API-DMAC7.html)
SK (1) SK286967B6 (cg-RX-API-DMAC7.html)
TR (1) TR200102385T2 (cg-RX-API-DMAC7.html)
TW (1) TWI240636B (cg-RX-API-DMAC7.html)
WO (1) WO2000048571A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200106677B (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200968B1 (en) * 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US7795246B2 (en) 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
PT1372611E (pt) * 2001-03-26 2006-08-31 Novartis Ag Composicao farmaceutica compreendendo uma estaurosporina francamente soluvel em agua, um tensioactivo et um polimero soluvel em agua
CA2444867C (en) 2001-05-16 2010-08-17 Novartis Ag Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
DE60213842T2 (de) * 2001-10-30 2007-09-06 Novartis Ag Staurosporin-derivate als hemmer der flt3-rezeptor-tyrosinkinase-wirkung
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
EP1531793A1 (en) * 2002-07-23 2005-05-25 Novartis AG Ophtalmic ointment composition comprising a drug, an ointment base and a solubiling/dispersing agent
US7842791B2 (en) 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions
TWI324604B (en) * 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
GB0419159D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
GT200500310A (es) * 2004-11-19 2006-06-19 Compuestos organicos
JP5546860B2 (ja) * 2006-08-16 2014-07-09 ノバルティス アーゲー 高結晶性治療化合物の固体分散体を製造するための方法
FR2918566B1 (fr) 2007-07-11 2009-10-09 Pierre Fabre Medicament Sa Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine.
US20090155352A1 (en) * 2007-11-20 2009-06-18 Cephalon, Inc. Microemulsion containing indolocarbazole compound and dosage forms containing the same
EP2229936B1 (en) * 2009-03-09 2015-05-06 PharmaSol GmbH Nanonized testosterone formulations for improved bioavailability
WO2011000811A2 (en) * 2009-06-30 2011-01-06 Novartis Ag Organic compounds
US20120322776A1 (en) * 2009-12-22 2012-12-20 Leo Pharma A/S Cutaneous composition comprising vitamin d analogue and a mixture of solvent and surfactants
JO3337B1 (ar) 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير
US9387446B2 (en) * 2011-09-22 2016-07-12 Ariel-University Research And Development Company Ltd. Emulsions and methods of making emulsions
RU2742650C2 (ru) * 2015-12-09 2021-02-09 Фосфейдженикс Лимитед Фармацевтический состав
MX383940B (es) 2015-12-09 2025-03-14 Phosphagenics Ltd Formulación farmacéutica que contiene tocol fosfato.
IL267006B2 (en) 2016-12-21 2024-11-01 Phosphagenics Ltd Process for phosphorylation of a complex alcohol with p4o10 at high temperatures, and products thereof
WO2021097256A1 (en) 2019-11-14 2021-05-20 Cohbar, Inc. Cxcr4 antagonist peptides

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963367A (en) 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US4735939A (en) 1987-02-27 1988-04-05 The Dow Chemical Company Insecticidal activity of staurosporine
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
DE3824034C1 (cg-RX-API-DMAC7.html) * 1988-07-15 1989-09-14 Gustav 7290 Freudenstadt De Memminger
KR0148748B1 (ko) * 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
AU668509B2 (en) 1991-04-19 1996-05-09 Affinity Biotech, Inc. Convertible microemulsion formulations
GB9113872D0 (en) 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
US6306421B1 (en) * 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
PT589843E (pt) * 1992-09-25 2002-04-29 Novartis Ag Composicoes farmaceuticas contendo ciclosporinas
US5981568A (en) * 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
US5639474A (en) 1993-07-01 1997-06-17 Hanmi Pharm. Ind., Ltd. Cyclosporin soft capsule composition
JPH09510182A (ja) 1993-11-17 1997-10-14 エルディーエス・テクノロジーズ・インコーポレーテッド カプセル封入されたドラッグデリバリー用透明液
GB9325395D0 (en) * 1993-12-11 1994-02-16 Ciba Geigy Ag Compositions
WO1995022331A1 (en) 1994-02-18 1995-08-24 Cephalon, Inc. Aqueous indolocarbazole solutions
WO1995032975A1 (en) * 1994-06-01 1995-12-07 Ciba-Geigy Ag Indolocarbazole derivatives for sensitizing multidrug-resistant cells to antitumor agents
IL129547A (en) * 1994-10-26 2001-01-11 Novartis Ag Pharmaceutical compositions comprising a macrolide and an acid
GB2308545B (en) 1994-10-26 1999-06-02 Novartis Ag Pharmaceutical microemulsion preconcentrates
EP0711557A1 (de) * 1994-11-09 1996-05-15 Ciba-Geigy Ag Pharmazeutische Formulierungsgrundlage
EP0733372A3 (de) * 1995-03-21 1998-05-20 Ciba-Geigy Ag Pharmazeutische Formulierungsgrundlage für Nanosuspensionen
WO1998013032A1 (en) 1996-09-27 1998-04-02 Trega Biosciences, Inc. Compositions of therapeutic agents suitable for oral administration
DE19641672A1 (de) 1996-10-10 1998-04-16 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen auf der Basis von ethylenoxidfreien und propylenoxidfreien Emulgatoren zur Herstellung von Mikroemulsionsgelen
US5827522A (en) 1996-10-30 1998-10-27 Troy Corporation Microemulsion and method
NZ314060A (en) 1997-01-13 1997-08-22 Bernard Charles Sherman Pharmaceutical microemulsion preconcentrate comprising cyclosporin dissolved in a solvent system comprising hydrophobic solvent(s) and surfactant(s)
SK285019B6 (sk) * 1997-01-30 2006-04-06 Novartis Ag Tvrdá želatínová tobolka
ATE265847T1 (de) 1997-07-29 2004-05-15 Upjohn Co Selbstemulgierbare formulierung enthaltend lipophile verbindungen
PL192080B1 (pl) 1997-07-29 2006-08-31 Upjohn Co Kompozycja farmaceutyczna zawierająca związek piranonowy
US6346511B1 (en) 1997-09-08 2002-02-12 Panacea Biotec Limited Pharmaceutical composition comprising cyclosporin
US6979456B1 (en) * 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
GB9814527D0 (en) * 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
AR013276A1 (es) 1998-07-31 2000-12-13 Panacea Biotec Ltd Composicion de ciclosporina transparente
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions

Also Published As

Publication number Publication date
TWI240636B (en) 2005-10-01
ES2326783T3 (es) 2009-10-20
NO331232B1 (no) 2011-11-07
TR200102385T2 (tr) 2002-09-23
GB9903547D0 (en) 1999-04-07
PL198330B1 (pl) 2008-06-30
US20080070897A1 (en) 2008-03-20
ATE430554T1 (de) 2009-05-15
ZA200106677B (en) 2003-01-14
IL144512A (en) 2011-03-31
ID30504A (id) 2001-12-13
WO2000048571A1 (en) 2000-08-24
SK11722001A3 (sk) 2001-12-03
DE60042151D1 (de) 2009-06-18
CZ20012931A3 (cs) 2001-11-14
KR100880859B1 (ko) 2009-01-30
ECSP083351A (es) 2008-08-29
HUP0105364A3 (en) 2003-02-28
US20020061873A1 (en) 2002-05-23
BRPI0008228B8 (pt) 2021-05-25
JP2012111763A (ja) 2012-06-14
BR0008228A (pt) 2001-10-30
US8722664B2 (en) 2014-05-13
MY128362A (en) 2007-01-31
IL144512A0 (en) 2002-05-23
NO20013964L (no) 2001-10-15
KR20080064914A (ko) 2008-07-09
AU3154200A (en) 2000-09-04
AU765776B2 (en) 2003-10-02
US8575147B2 (en) 2013-11-05
CN100367930C (zh) 2008-02-13
CL2009001682A1 (es) 2010-07-23
CZ303979B6 (cs) 2013-07-31
AR022589A1 (es) 2002-09-04
PL350556A1 (en) 2002-12-16
NO20013964D0 (no) 2001-08-15
SK286967B6 (sk) 2009-08-06
DK1152750T3 (da) 2009-08-24
EP1152750A1 (en) 2001-11-14
CA2362277C (en) 2010-03-30
CA2362277A1 (en) 2000-08-24
HK1045807B (zh) 2008-12-05
PT1152750E (pt) 2009-08-07
SI1152750T1 (sl) 2009-10-31
EP1152750B1 (en) 2009-05-06
RU2266121C2 (ru) 2005-12-20
HK1045807A1 (zh) 2002-12-13
CN1339963A (zh) 2002-03-13
JP2002537242A (ja) 2002-11-05
PE20001499A1 (es) 2001-01-12
IL192666A0 (en) 2009-02-11
KR20010093281A (ko) 2001-10-27
NZ513529A (en) 2003-10-31
BRPI0008228B1 (pt) 2016-08-23
HUP0105364A2 (hu) 2002-05-29
AR082579A2 (es) 2012-12-19
US20140056974A1 (en) 2014-02-27

Similar Documents

Publication Publication Date Title
JP5057610B2 (ja) 自然分散性ｎ−ベンゾイルスタウロスポリン組成物
AU765935B2 (en) Substantially oil-free cyclosporin compositions
EP1082119B1 (en) Microemulsion preconcentrates containing a piperidine substance p antagonist
KR20140018858A (ko) 알리스포리비르를 포함하는 제약 조성물
RU2397759C2 (ru) Микроэмульсионные композиции, включающие антагонисты вещества р
MXPA01008293A (en) Spontaneously dispersible n-benzoyl staurosporine compositions
HK1035137B (en) Microemulsion preconcentrates containing a piperidine substance p antagonist

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100803

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101101

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101203

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101210

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20101224

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120105

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120302

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120608

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120710

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120731

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150810

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 5057610

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees